CD163 and primary cutaneous T-cell non-Hodgkin lymphoma: The presence of CD163-expressing M2 TAMs has been associated with poor clinical outcomes in CTCL, and depletion of M2 macrophage was found to suppress CTCL development in vivo10,47,48.